1.GaedeP,Lund-AndersenH,ParvingHH,etal.Effectofamultifactorialinterventiononmortalityintype2diabetes.NEnglJMed2008;358:580–5912.BuseJB,GinsbergHN,BakrisGL,etal.Primarypreventionofcardiovasculardiseasesinpeoplewithdiabetesmellitus:ascientificstatementfromtheAmericanHeartAssociationandtheAmericanDiabetesAssociation.DiabetesCare2007;30:162–1723.AntithromboticTrialists’(ATT)Collaboration.Aspirinintheprimaryandsecondarypreventionofvasculardisease:collaborativemeta-analysisofindividualparticipantdatafromrandomisedtrials.Lancet2009;373:1849–18604.GargJP,BakrisGL.Microalbuminuria:markerofvasculardysfunction,riskfactorforcardiovasculardisease.VascMed2002;7:35–435.KlausenK,Borch-JohnsenK,Feldt-RasmussenB,etal.Verylowlevelsofmicroalbuminuriaareassociatedwithincreasedriskofcoronaryheartdiseaseanddeathindependentlyofrenalfunction,hypertension,anddiabetes.Circulation2004;110:32–356.SelvinE,SteffesMW,ZhuH,etal.GlycatedHemoglobin,Diabetes,andCardiovascularRiskinNondiabeticAdults.NEnglJMed2010;362:800-8117.AmericanDiabetesAssociation.StandardsofMedicalCareinDiabetes—2010.DiabetesCare2010,33(SUPPL1):S1-S618.SkylerJS,BergenstalR,BonowRO,etal.AmericanDiabetesAssociation,AmericanCollegeofCardiologyFoundation,AmericanHeartAssociation.Intensiveglycemiccontrolandthepreventionofcardiovascularevents:implicationsoftheACCORD,ADVANCE,andVAdiabetestrials:apositionstatementoftheAmericanDiabetesAssociationandascientificstatementoftheAmericanandtheAmericanHeartAssociation.DiabetesCare2009;32:187–1929.ChobanianAV,BakrisGL,BlackHR,etal.NationalHeart,Lung,andBloodInstituteJointNationalCommitteeonPrevention,Detection,Evaluation,andTreatmentofHighBloodPressure,NationalHighBloodressureEducationProgramCoordinatingCommittee.TheSeventhReportoftheJointNationalCommitteeonPrevention,Detection,Evaluation,andTreatmentofHighBloodPressure:theJNC7report.JAMA2003;289:2560–257210.ManciaaG,LaurentbS,Agabiti-RoseicE,etal.ReappraisalofEuropeanguidelinesonhypertensionmanagement:aEuropeanSocietyofHypertensionTask.Forcedocument.JournalofHypertension2009,27:2121–215811.TheACCORDStudyGroup.EffectsofIntensiveBlood-PressureControlinType2DiabetesMellitus.NEnglJMed2010;362:1575-158512.LindholmLH,IbsenH,Dahlo¨fB,etal.LIFEStudyGroup.CardiovascularmorbidityandmortalityinpatientswithdiabetesintheLosartanIntervention.ForEndpointreductioninhypertensionstudy(LIFE):arandomisedtrialagainstatenolol.Lancet2002;359:1004–101013.BerlT,HunsickerLG,LewisJB,etal.IrbesartanDiabeticNephropathyTrialCollaborativeStudyGroup.CardiovascularoutcomesintheIrbesartanDiabeticNephropathyTrialofpatientswithtype2diabetesandovertnephropathy.AnnInternMed2003;138:542–54914.LaffelLM,McGillJB,GansDJ.Thebeneficialeffectofangiotensin-convertingenzymeinhibitionwithcaptoprilondiabeticnephropathyinnormotensiveIDDMpatientswithmicroalbuminuria.NorthAmericanMicroalbuminuriaStudyGroup.AmJMed1995;99:497–50415.BakrisGL,WilliamsM,DworkinL,etal.Preservingrenalfunctioninadultswithhypertensionanddiabetes:aconsensusapproach:NationalKidney.FoundationHypertensionandDiabetesExecutiveCommitteesWorkingGroup.AmJKidneyDis2000;36:646–66116.ParhoferKG,MünzelF,KreklerM.Effectoftheangiotensinreceptorblockerirbesartanonmetabolicparametersinclinicalpractice:theDO-ITprospectiveobservationalstudy.CardiovascularDiabetology2007,6:3617.ParvingHH,LehnertH,Br&ouml;chner-MortensenJ,etal;IrbesartaninPatientswithType2DiabetesandMicroalbuminuriaStudyGroup.Theeffectofirbesartanonthedevelopmentofdiabeticnephropathyinpatientswithtype2diabetes.NEnglJMed2001;345:870-87818.宗文漪，杨文英，向红丁，等。